Korro Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KRRO Nasdaq 2836 www.korrobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Korro Bio, Inc.

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 8th, 2026 6:00 am
Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot - Nov 14th, 2025 8:14 pm
Korro Bio Plummets To A Record Low On A Big Setback In RNA Editing - Nov 13th, 2025 2:30 pm
Top Midday Decliners - Nov 13th, 2025 12:18 pm
Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls - Nov 13th, 2025 7:45 am
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing - Nov 13th, 2025 4:12 am
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2025 3:40 pm
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs - Nov 12th, 2025 2:05 pm
Korro to Participate in Upcoming Investor and Scientific Conferences - Sep 2nd, 2025 2:30 pm
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Deliver On Growth Plans? - Aug 26th, 2025 4:58 am
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates - Aug 12th, 2025 5:00 am
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 - Jul 21st, 2025 6:00 am
Korro to Participate in Upcoming Investor Conferences - May 14th, 2025 2:05 pm
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright - May 9th, 2025 8:31 am
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - May 7th, 2025 2:30 pm
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - Apr 1st, 2025 5:30 am
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Mar 19th, 2025 4:51 am
Korro Reports Full Year 2024 Financial Results and Provides Business Updates - Mar 18th, 2025 5:00 am
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - Mar 14th, 2025 6:00 am
Korro to Present at the TD Cowen 45th Annual Health Care Conference - Feb 26th, 2025 6:00 am